<html>
<head>PUBMED IDs for LPAR5</head>
<body bgcolor='#C5F0F2'><h1>LPAR5</h1><a href='https://pubmed.ncbi.nlm.nih.gov/20055701/'>LPA receptors: subtypes and biological actions.</a> March 18  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/25294670/'>Down-regulation of LPA receptor 5 contributes to aberrant LPA signalling in EBV-associated nasopharyngeal carcinoma.</a> March 21  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25294632/'>Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.</a> January 20  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25294623/'>Establishment of a quantitative PCR system for discriminating chitinase-like proteins: catalytically inactive breast regression protein-39 and Ym1 are constitutive genes in mouse lung.</a> February 27  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/26123684/'>Genetic and Functional Evidence Supports LPAR1 as a Susceptibility Gene for Hypertension.</a> November 6  2015<br></body></html>
